Search - tctmd.com

Displaying 61 - 80 of 95

Sort: Relevancy | Date

Presentation

Safety and Efficacy of TAVR With Continuation of Oral Anticoagulation

April 18, 2019

News Daily News

Continuing Anticoagulation During TAVR: New Data Offer a Glimpse of What Works

Shelley Wood

April 16, 2019

News Conference News EHRA 2019

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

Todd Neale

March 25, 2019

News Conference News CRT 2019

One-Year Data on Low-Risk TAVR Continue to Show Good Safety: LRT

Yael L. Maxwell

March 04, 2019

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

Todd Neale

January 09, 2019

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

News Conference News ESC 2018

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

Michael O'Riordan

August 25, 2018

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2018

Caitlin E. Cox

April 30, 2018

News Conference News CRT 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

Michael O'Riordan

March 07, 2018

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

Shelley Wood

December 28, 2017

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Shelley Wood

August 27, 2017

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Shelley Wood

June 19, 2017

News Daily News

Anticoagulation in Pregnant Women With Mechanical Heart Valves: A Balancing Act

Caitlin E. Cox

May 31, 2017

Presentation EuroPCR 2017

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

Presenter: Lucas Boersma, Martin W. Bergmann

May 18, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

News Conference News CRT 2017

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Michael O'Riordan

February 20, 2017

Advertisement

Safety and Efficacy of TAVR With Continuation of Oral Anticoagulation

Continuing Anticoagulation During TAVR: New Data Offer a Glimpse of What Works

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

One-Year Data on Low-Risk TAVR Continue to Show Good Safety: LRT

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

TCTMD’s Top 10 Most Popular Stories for April 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

TCTMD’s Top 10 Most Popular Stories for December 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Anticoagulation in Pregnant Women With Mechanical Heart Valves: A Balancing Act

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day Three

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content